Trodusquemine

Trodusquemine.svg

Trodusquemine (also known as MSI-1436) is an experimental drug that has been investigated for its potential use in treating obesity and diabetes. It is a naturally occurring aminosterol derived from the dogfish shark.

Mechanism of Action

Trodusquemine functions primarily as an inhibitor of the enzyme protein tyrosine phosphatase 1B (PTP1B). PTP1B is a negative regulator of the insulin and leptin signaling pathways. By inhibiting PTP1B, trodusquemine enhances the sensitivity of these pathways, which can lead to improved glucose homeostasis and reduced body weight.

Research and Development

Trodusquemine has been the subject of various preclinical and clinical studies. In animal models, it has shown promise in reducing body weight and improving insulin resistance. Early-phase clinical trials have been conducted to evaluate its safety and efficacy in humans.

Potential Applications

The primary potential applications of trodusquemine are in the treatment of obesity and type 2 diabetes. By improving insulin sensitivity and promoting weight loss, it may offer a novel therapeutic approach for these conditions.

Side Effects and Safety

As an experimental drug, the full profile of side effects and long-term safety of trodusquemine is not yet fully understood. Early clinical trials have reported some adverse effects, but further research is needed to establish a comprehensive safety profile.

See Also

• Obesity
• Diabetes
• Insulin resistance
• Leptin
• Protein tyrosine phosphatase 1B

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian